<DOC>
	<DOCNO>NCT02334865</DOCNO>
	<brief_summary>This phase I trial study safety SVN53-67/M57-KLH peptide vaccine incomplete Freund 's adjuvant together sargramostim treat patient newly diagnose multiple myeloma receive lenalidomide maintenance therapy . Vaccines make survivin peptide may help body build effective immune response kill cancer cell express survivin . Incomplete Freund 's adjuvant may help stimulate body 's immune response vaccine treatment . Colony-stimulating factor , sargramostim , may increase production blood cell . Lenalidomide may stop growth cancer cell block enzymes need cell growth . Giving SVN53-67/M57-KLH peptide vaccine incomplete Freund 's adjuvant sargramostim start lenalidomide maintenance therapy may better treatment multiple myeloma .</brief_summary>
	<brief_title>SVN53-67/M57-KLH Peptide Vaccine Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine toxicity profile SVN53-67/M57-KLH peptide ( SVN53-67/M57-KLH peptide vaccine ) Montanide ISA 51 ( incomplete Freund 's adjuvant ) plus GM-CSF ( sargramostim ) ( vaccine ) , give start lenalidomide maintenance patient multiple myeloma . SECONDARY OBJECTIVES : I . To measure immune response induce SVN53-67/M57-KLH Montanide ISA 51 plus GM-CSF , either alone lenalidomide maintenance add either vaccine . TERTIARY OBJECTIVES : I . To collect preliminary data therapeutic efficacy combination multiple myeloma , include response rate , time progression disease progression slope . II . To test human leukocyte antigen ( HLA ) type survivin positivity affect immune response induce SVN53-67/M57-KLH Montanide ISA 51 plus GM-CSF . OUTLINE : Patients assign 1 2 group . GROUP A : Patients receive SVN53-67/M57-KLH peptide vaccine incomplete Freund 's adjuvant subcutaneously ( SC ) sargramostim SC every 2 week week 0 , 2 , 4 , 6 4 dos receive booster week 12 . Beginning week 4 , patient receive lenalidomide maintenance therapy orally ( PO ) daily ( QD ) absence disease progression unacceptable toxicity . GROUP B : Patients receive SVN53-67/M57-KLH peptide vaccine incomplete Freund 's adjuvant SC sargramostim SC every 2 week week 4 , 6 , 8 , 10 4 dos receive booster week 16 . Beginning week 0 , patient receive lenalidomide maintenance therapy PO QD absence disease progression unacceptable toxicity . After completion study treatment , patient follow 16 , 20 , 24 week every 3 month 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>Understand voluntarily sign informed consent form Able adhere study visit schedule protocol requirement Patients newly diagnose multiple myeloma least partial response induction therapy base International Working Group ( IWG ) Uniform Response Criteria Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 study entry Must free systemic infection ; subject active infection ( whether require antibiotic therapy ) may eligible complete resolution infection ; subject antibiotic therapy must antibiotics least 7 day begin treatment Absolute neutrophil count &gt; = 750/mm^3 Platelet count &gt; = 30,000/mm^3 Creatinine clearance &gt; = 30 mL/minutes Total bilirubin = &lt; 2 mg/dL Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 3 x upper limit normal ( ULN ) All study participant must register mandatory Revlimid Risk Evaluation Mitigation Strategy ( REMS ) ® , willing able comply requirement Revlimid REMS® Females reproductive potential must adhere scheduled pregnancy test require Revlimid REMS® program Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant acetylsalicylic acid , ASA , may use warfarin low molecular weight heparin ) Disease free prior malignancy &gt; 2 year exception currently treat basal cell carcinoma , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast All study participant must one HLA allele : HLAA*02 , HLAA*03 , HLAA*11 , HLAA*24 Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form Pregnant breast feeding female ; ( lactate female must agree breast feed take lenalidomide ) Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study determine Principal Investigator Chemotherapy , immunotherapy , radiotherapy , radiosurgery , interferon ( e.g . IntronA® ) , allergy desensitization injection , growth factor ( e.g . Procrit® , Aranesp® , Neulasta® ) , interleukin ( e.g . Proleukin® ) investigational therapeutic medication within 4 week study entry Known hypersensitivity thalidomide , lenalidomide , Keyhole Limpet Hemocyanin ( KLH ) , granulocyte colonymacrophage stimulate factor ( GMCSF ) The development erythema nodosum characterize desquamate rash take thalidomide similar drug Known seropositive active viral infection human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) ; patient seropositive hepatitis B virus vaccine eligible Any prior autoimmune disorder require cytotoxic immunosuppressive therapy autoimmune disorder visceral involvement Patients know diagnosis plasma cell leukemia Systemic corticosteroid therapy &gt; 2 mg dexamethasone equivalent per day study entry Patients prior autologous allogeneic stem cell transplant ; prior stem cell collection allow Life expectancy le 4 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>